Research by Zhonghua Liu et al. (Liu, 2009) revealed that HXZQC inhibited the lung index of mice infected with avian influenza virus (AIV) H5N1, reduced the development of lung disease, and enhanced the antiviral capacity of mice infected with AIV. The death rate of the infected mice was reduced through regulation of the gastrointestinal tract and strengthening of the stomach Qi. Hongkun Zhang (Zhang, 2013) found that HXZQC inhibited growth of Vibrio parahaemolyticus, Candida albicans, Staphylococcus aureus, and Streptococcus pneumoniae. Research by Wang et al. (2012) found that HXZQC inhibited lipopolysaccharide (LPS)-stimulated expression of proinflammatory cytokines by macrophages and inhibited epithelial barrier disorder induced by interferon-γ (IFN-γ), regulating immunity and improving gastroenteric function. Research by Chunyuan Li et al. (Li et al., 2017) showed that HXZQC significantly improved the thymus coefficient, spleen coefficient and immunoglobulin G (IgG) levels of mice with dampness obstructing spleen-stomach, and enhanced the immune function of the mice. Studies by Yinghui He et al. (He et al., 2006) and Shaobo Zong et al. (Zong et al., 2015) discovered that HXZQC had therapeutic effects in mice with Bacillus dysenteriae and Salmonella typhimurium-induced diarrhea (BSD mice), mice with bacterial enteritis, and model rats with diarrhea-predominant irritable bowel syndrome (IBS). Clinical symptoms were significantly improved, which might be due to effects on the balance of CD4+ and CD8+ T lymphocytes, and reduction of interleukin-2 (IL-2), interleukin-10 (IL-10), interleukin-1β (IL-1β), and tumor necrosis factor alpha (TNF-α) levels. The results suggested that HXZQC, via immune-regulation and anti-inflammatory activity, could have therapeutic effects against many gastrointestinal disorders. Research by Hefei Huang et al. (Huang et al., 2016) showed that HXZQC extracts had a positive regulatory effect on intestinal dysfunction, and had therapeutic efficacy in model rats with diarrhea-predominant IBS. Efficacy was mediated by improving serum NO levels and reducing the concentrations of 5-hydroxytryptamine (5-HT), plasma motilin, and colonic somatostatin.